IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion
IL1RAP-targeting antibodies can reduce the expression of inflammatory cytokines and markers of adhesion in endothelial cells, which may be of importance for future putative targeted treatments against cardiovascular disease.
Authors
- Karin Fransén (ORCID: https://orcid.org/0000-0002-9826-0462)
- Madelene Lindkvist (ORCID: https://orcid.org/0000-0002-2732-158X)
- Caitríona Grönberg (ORCID: https://orcid.org/0009-0000-3776-5566)
- Geena Varghese Paramel (ORCID: https://orcid.org/0000-0002-4589-6440)
- Anna Göthlin Eremo (ORCID: https://orcid.org/0000-0002-7498-7157)
- Sara Rattik (ORCID: https://orcid.org/0000-0002-5172-6456)
- Sheikh Anisul Haque (ORCID: https://orcid.org/0000-0002-0927-4126)
- Camilla Rydberg Millrud (ORCID: https://orcid.org/0000-0002-5873-2197)
- David Liberg (ORCID: https://orcid.org/0009-0009-0645-746X)
- Allan Sirsjö (ORCID: https://orcid.org/0000-0002-0278-4510)
Institutions
- Örebro University (SE)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1161/jaha.124.039557
- Citations
- 4
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 3.19